LRRC32 and neoplasm: This strategy would not only target platelets but also activated Treg and GARP+ tumor cells, leading to the modulation of the inhibitory tumor microenvironment with the overall aim to overcome cancer’s resistance to immunotherapy through this combinatorial approach.